Abstracts tagged "B cells"

Abstract Number: 1760 • 2012 ACR/ARHP Annual Meeting
A Gene Expression Signature to Monitor Depletion of Plasma Cells Following MEDI-551 (anti-CD19) Administration
Katie Streicher¹, Chris Morehouse¹, Christopher Groves², Bhargavi Rajan², Fernanda Pilataxi¹, Kim Lehmann¹, Philip Brohawn¹, Kathleen McKeever³, Volker Knappertz⁴, Ronald Herbst², Yihong Yao¹ and Koustubh Ranade¹, ¹Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ²Respiration, Inflammation and Autoimmunity, MedImmune, LLC, Gaithersburg, MD, ³Translational Sciences, MedImmune, Gaithersburg, MD, ⁴Clinical, MedImmune, LLC, Gaithersburg, MD
Background/Purpose: Production of pathogenic autoantibodies by inappropriately self-reactive plasma cells (PC) is a hallmark of autoimmune diseases. MEDI-551 is an anti-CD19 antibody which is expected…
Abstract Number: 1755 • 2012 ACR/ARHP Annual Meeting
The Alternative ΔCD20 Transcript Variant Is Not Expressed in B Cells and Synovial Tissue From Patients with Rheumatoid Arthritis
Clémentine Gamonet¹, Marina Deschamps², Béatrice Gaugler³, Philippe Saas⁴, Isabelle Auger⁵, Christophe Ferrand⁴, Eric Toussirot⁶ and CIC BT506⁷, ¹INSERM UMR1098/ Etablissement Français du Sang / Université de Franche Comté, France, ²INSERM UMR1098 / Etablissement Français du Sang/ Université de Franche Comté, Besançon, France, ³EFS Bourgogne Franche Comté, INSERM UMR1098 / Etablissement Français du Sang / Université de Franche Comté, Besançon, France, ⁴Etablisement Français du Sang ; Université de Franche Comté, INSERM UMR1098, Besançon, France, ⁵Université Aix Marseille II, INSERM UMR1097, Marseille, France, ⁶University Hospital, CIC Biotherapy 506 and Rheumatology and EA 4266 Pathogens and Inflammation, Besançon, France, ⁷Chru, Clinical Investigation Center Biotherapy 506, Besançon, France
Background/Purpose: determining predictive factors for response to biologics may help to select appropriate treatment in patients with RA. Rituximab (RTX) is a chimeric monoclonal antibody…
Abstract Number: 510 • 2012 ACR/ARHP Annual Meeting
IL-7 and IL-7 Receptor Blockade to Selectively Inhibit TLR7-Induced B Cell Activation in Primary Sjögren’s Syndrome
A. Bikker¹, C.R. Willis², A.a. Kruize¹, J.W.J. Bijlsma³, F.P.J.G. Lafeber³ and J.A.G. van Roon⁴, ¹Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Amgen Inc., Seattle, WA, ³Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Rheumatology & Clinical Immunology/Lab Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Toll-like receptors (TLRs) are involved in the recognition of nucleic acids (viral, bacterial, and possibly self) and have been implicated in several auto-immune diseases.…
Abstract Number: 1761 • 2012 ACR/ARHP Annual Meeting
Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Anti-CD19 Monoclonal Antibody That Co-Engages the B Cell Antigen Receptor and the FcγRIIb Inhibitory Receptor
Seung Y. Chu¹, Karen Yeter², Roshan Kotha³, Erik Pong¹, Yvonne Miranda¹, Hsing Chen¹, Sung-Hyung Lee¹, Irene Leung¹, John R. Desjarlais¹, William Stohl² and David E. Szymkowski⁴, ¹Xencor, Inc., Monrovia, CA, ²Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ³Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ⁴Biotherapeutics, Xencor, Inc., Monrovia, CA
Background/Purpose: XmAb®5871 is a humanized and Fc-engineered antibody that coengages CD19, part of the B cell receptor (BCR) complex, with the inhibitory receptor FcγRIIb (CD32b).…
Abstract Number: 1756 • 2012 ACR/ARHP Annual Meeting
Peripheral Blood B Cell Subsets and BAFF/APRIL Receptor Expression, Together with Circulating BAFF and APRIL Levels, Are Disturbed in Rheumatoid Arthritis but Not in Ankylosing Spondylitis
Béatrice Gaugler¹, Caroline Laheurte², Ewa Bertolini³, Daniel Wendling⁴, Philippe Saas⁵, Eric Toussirot⁶ and CIC BT506⁷, ¹EFS Bourgogne Franche Comté, INSERM UMR1098 / Etablissement Français du Sang / Université de Franche Comté, Besançon, France, ²Etablissement Français du Sang/ Université de Franche Comté / CBT506 / CHRU, INSERM UMR1098 / Plateforme Biomonitoring, Besançon, France, ³University Hospital, Rheumatology, Besançon, France, ⁴Service de Rhumatologie, Minjoz University Hospital, Besancon, France, ⁵Etablisement Français du Sang ; Université de Franche Comté, INSERM UMR1098, Besançon, France, ⁶Université de Franche Comté , CHRU, CIC Biotherapy 506 and Rheumatology and EA 4266 Pathogens and Inflammation, Besançon, France, ⁷Chru, Clinical Investigation Center Biotherapy, Besançon, France
Background/Purpose: B cells play a critical role in systemic autoimmune disease and especially rheumatoid arthritis (RA). BAFF and APRIL are involved in B cell activation…
Abstract Number: 514 • 2012 ACR/ARHP Annual Meeting
Frequencies and Numbers of Circulating IL-10 Producing Regulatory B Cells Are Not Disturbed in Pss-Patients but Correlate Negatively with the EULAR Sjögren Syndrome Disease Activity Score (ESSDAI)
Wayel H. Abdulahad¹, Gwenny Verstappen¹, Arjan Vissink², Minke G. Huitema¹, Petra M. Meiners², Hendrika Bootsma³ and Frans Kroese⁴, ¹Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ²Oral and Maxillofacial Surgery, University Medical Center Groningen, Groningen, Netherlands, ³Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁴University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Recently, a specific and functionally important subset of regulatory B cells (Breg) that negatively regulate autoimmunity and inflammation has been described. Breg cells exert…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.